Qitai Pharmaceutical: It is expected that the net profit will be a loss of 19 million to 15 million yuan in the first half of 2025.

Enlighten Pharmaceuticals announcement, it is expected that the net profit attributable to shareholders of the listed company from January 1, 2025 to June 30, 2025 will be a loss of 19-15 million yuan, compared to a loss of 23.3946 million yuan in the same period last year; the net profit after deducting non-recurring gains and losses is expected to be a loss of 25-20 million yuan, compared to a loss of 24.389 million yuan in the same period last year; the basic earnings per share are expected to be a loss of 0.0793-0.0626 yuan per share, compared to a loss of 0.0977 yuan per share in the same period last year. The company has been affected by factors such as the market environment in the past two years, resulting in a decline in total operating income, rising prices of some raw materials, and a decrease in overall gross profit margin and profitability level.